Norwegian authorities confirmed this Thursday the death of a second person and the Swedish death of another from serious thromboembolic complications tafter receiving the AstraZeneca vaccine against covid-19.
Norway has registered a total of six cases with an unusual clinical picture that includes low platelets, clots in blood vessels and bleeding, similar to that detected in several countries.
A group of doctors from the Oslo University Hospital had announced hours before that the immune reaction of the AstraZeneca vaccine It is the cause of the thromboses suffered by three health workers admitted to that center over the weekend, one of them died last Sunday.
“We have made several findings that may explain the clinical course of the patients. Those findings support our hypothesis that they had a strong immune response that triggered the formation of antibodies, which could in turn activate platelets and cause thrombi,” he said Pål André Holme, head of the medical team.
NORWAY MAINTAINS THE SUSPENSION OF THE VACCINE
Several countries such as France, Italy or Spain have confirmed that they will resume vaccination with AstraZeneca, but not Norway, which will continue to study the episodes recorded in this country.
“We are analyzing in detail if there is a relationship between the vaccine and the cases. We will study the EMA analysis and report on ours at the end of next week “, said the director of the Institute of Public Health, Camilla Stoltenberg.
DENMARK AND SWEDEN ALSO MAINTAIN SUSPENSION
Denmark, the first country to suspend the use of the AstraZeneca vaccine a week ago, also keep that decision. The Danish Medicines Agency reported today that a total of ten cases with thrombosis have been recorded after receiving the vaccine, although it has not yet been determined whether there is a connection.
The Danish authorities communicated a few days ago the death of a woman under the age of 60 with an unusual clinical picture.
Her Swedish equivalent confirmed the death of another woman in her 60s today and without previous ailments with a similar clinical picture and another suspicious case that is being investigated. Sweden, which was one of the last countries to join the suspension of AstraZeneca, also reported that this decision will stand for a while.
“The Public Health Agency needs a few days to analyze the situation of how the vaccine can be used in Sweden,” said its director, Johan Carlson.
– .
